Holen Sie sich die Stockscreener-App
92.54
0.53%
0.49
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$92.05
Offen:
$91.75
24-Stunden-Volumen:
995.18K
Relative Volume:
0.61
Marktkapitalisierung:
$44.80B
Einnahmen:
$9.91B
Nettoeinkommen (Verlust:
$1.02B
KGV:
45.14
EPS:
2.05
Netto-Cashflow:
$665.00M
1W Leistung:
+6.37%
1M Leistung:
+2.98%
6M Leistung:
-2.09%
1J Leistung:
+17.14%
1-Tages-Spanne:
$91.29
$92.92
1-Wochen-Bereich:
$87.94
$92.96
52-Wochen-Spanne:
$77.54
$101.10
Alcon Inc Stock (ALC) Company Profile
Vergleichen Sie ALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Lobbying Update: $150,000 of ALCON VISION LLC lobbying was just disclosed - Nasdaq
Aniridia Treatment Market Is Going to Boom | Major Giants Alcon, Santen Pharmaceutical, Johnson & Johnson Vision - openPR.com
There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital - Yahoo Finance
Alcon lines up product launches in India, bets on rising demand for advanced eye care - MSN
Alcon: A Clear Vision, But Fully Valued (NYSE:ALC) - Seeking Alpha
GE HealthCare Hires Alcon Exec Jeannette Bankes as Patient Care Solutions CEO - Medical Product Outsourcing
Ophthalmic Devices Market Set to Attain Valuation of US$ 83.33 Billion By 2033 | Astute Analytica - GlobeNewswire Inc.
Here’s Why ClearBridge Large Cap Growth Strategy Sold Alcon (ALC) - Insider Monkey
Tesla, Warner Bros fend off some claims in 'Blade Runner 2049' ad dispute - Reuters
Alcon (VTX:ALC) Seems To Use Debt Quite Sensibly - simplywall.st
Alcon Scoops Up Aurion Biotech With Intent of Advancing Ophthalmology Cell Therapy AURN001 - CGTLive®
Bernstein raises Alcon stock price target to CHF99 from CHF97.50 - Investing.com Canada
Alcon, Aurion Reach Accord in Dispute Over Public Offering - Bloomberg Law News
Bernstein raises Alcon stock price target to CHF99 from CHF97.50 By Investing.com - Investing.com South Africa
Dr. Jeffrey Martin of SightMD Becomes One of the First on Long Island to Implant the new Clareon® PanOptix® Pro Lens by Alcon - PRWeb
Alcon Publishes Agenda for 2025 Annual General Meeting - Business Wire
ALC Stock May Rise With the Introduction of PanOptix Pro in US - MSN
Alcon Introduces Clareon PanOptix Pro Intraocular Lens - Medical Product Outsourcing
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix - GuruFocus
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter - Business Wire
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals - Yahoo Finance
Dry Eye Disease Market Growth in Future Scope 2025-2032 | - openPR.com
KeyBanc raises Alcon stock price target to $112 on growth outlook - Investing.com Canada
KeyBanc raises Alcon stock price target to $112 on growth outlook By Investing.com - Investing.com South Africa
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space - TradingView
Deutsche Bank lifts Alcon stock price target to CHF96 from CHF92 - Investing.com Canada
Deutsche Bank lifts Alcon stock price target to CHF96 from CHF92 By Investing.com - Investing.com South Africa
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval - MSN
Stifel maintains Alcon stock Buy rating, $100 target By Investing.com - Investing.com Australia
Citi maintains Alcon stock Buy rating, CHF99.00 target By Investing.com - Investing.com South Africa
Mizuho lifts Alcon stock price target to $120, maintains Outperform By Investing.com - Investing.com Canada
Taxation With Representation: Norton Rose, Latham, Ashurst - Law360
Oppenheimer Remains a Buy on Alcon (ALC) - The Globe and Mail
Stifel maintains Alcon stock Buy rating, $100 target - Investing.com
Alcon stock price target raised to $110 at Needham - Investing.com India
Alcon stock price target raised to $110 at Needham By Investing.com - Investing.com Australia
Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Mizuho lifts Alcon stock price target to $120, maintains Outperform - Investing.com
Jefferies raises Alcon stock price target to $115, maintains Buy - Investing.com India
Jefferies raises Alcon stock price target to $115, maintains Buy By Investing.com - Investing.com South Africa
Citi maintains Alcon stock Buy rating, CHF99.00 target - Investing.com India
Alcon (VTX:ALC) ascends 4.7% this week, taking five-year gains to 80% - Yahoo Finance
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Cell Therapy for Corneal Endothelial Disease - VisionMonday.com
Alcon Inc’s Acquisition of LENSAR Inc - Global Legal Chronicle
Alcon: Innovation, Commercial Excellence, and Robust Momentum Mark Successful Capital Markets Day - Morningstar
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):